Nasdaq

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...
Business Insider

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the ...
Seeking Alpha

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases

Beam Therapeutics (BEAM) is continuing to fire on all cylinders with respect to the development of its ex vivo hematopoietic stem cell transplant gene therapy known as BEAM-101. The reason why is ...
Nasdaq

Beam Therapeutics to Present Updated Data on BEAM-101 in Sickle Cell Disease at EHA2025 Conference

Beam Therapeutics will present new BEAM-101 data for sickle cell disease at EHA2025, detailing safety and efficacy in 17 patients. Beam Therapeutics Inc. has announced that it will present updated ...
WGHP

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology ...

CAMBRIDGE, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, announces new safety and ...
Seeking Alpha

Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal

The last time I wrote about Beam Therapeutics Inc. (BEAM) it was in a Seeking Alpha article entitled "Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases." I rated the ...